American Journal of Transplantation: Volume 18, Number 10, October 2018

On the cover this month: The advent of direct‐acting antiviral agents with efficacy for HCV provides numerous new options for the treatment of HCV in recipients, regardless of organ. These treatment strategies are changing the calculus for clinicians who must weigh the odds of HCV disease progression (or acquisition) versus the utility of reducing wait time by accepting an HCV‐positive organ. This month, AJT covers this topic in depth, presenting numerous original articles, editorials, and reviews evaluating the impact of pre–, peri–, and post–transplant use of direct‐acting HCV‐specific antiviral therapies. Cover design by Megan Llewellyn, Duke University Department of Surgery .